<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841944</url>
  </required_header>
  <id_info>
    <org_study_id>2012/14890</org_study_id>
    <secondary_id>2012-004478-25</secondary_id>
    <nct_id>NCT01841944</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction</brief_title>
  <acronym>OMEMI</acronym>
  <official_title>Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asker &amp; Baerum Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate the possible effects of supplementation with
      1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during
      a follow-up period of 2 years in an elderly population after having experienced an acute
      myocardial infarction.

      The hypothesis is that this supplementation on top of modern therapy will reduce the combined
      cardiovascular end-point of death, non-fatal myocardial infarction, stroke,
      revascularizations or hospitalization for new or worsened heart failure with at least 30%.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined total mortality, first event of non-fatal myocardial infarction, stroke, revascularization or hospital admission for new or worsened heart failure.</measure>
    <time_frame>24months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of new onset atrial fibrillation</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1027</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Heart Failure</condition>
  <condition>Myocardial Revascularization</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pikasol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pikasol®, 3 capsules (1.8 g EPA+DHA)/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corn oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3x capsules of corn oil pr day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pikasol</intervention_name>
    <description>Pikasol®, 3 capsules (1.8 g EPA+DHA)/day</description>
    <arm_group_label>Pikasol</arm_group_label>
    <other_name>omega-3</other_name>
    <other_name>polyunsaturated fatty acids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Corn oil</intervention_name>
    <description>Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer</description>
    <arm_group_label>Corn oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute myocardial infarction discharged from hospital alive

        Exclusion Criteria:

          -  Being part of another randomized trial

          -  Documented intolerance for omega-3 fatty acids

          -  Additional disease state that is thought to be incompatible with compliance to the
             study drugs

          -  Additional disease state thought to reduce survival for the follow-up time of 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Arnesen, MD Phd</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Clinical Heart Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Svein Solheim, MD phd</last_name>
    <role>Study Director</role>
    <affiliation>Center for Clinical Heart Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingebjørg Seljeflot, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Center for Clinical Heart Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian Laake, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Clinical Heart Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peder Myhre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Clinical Heart Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Are A Kalstad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Clinical Heart Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asker and Bærum Hospital</name>
      <address>
        <city>Rud</city>
        <state>Bærum</state>
        <zip>1309</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus university hospital HF</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital(Ullevaal)</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Are Annesønn Kalstad</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Fatty Acids, Omega-3</keyword>
  <keyword>Aged</keyword>
  <keyword>Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

